Elan Corporation, Plc (ELN) upgraded to Mkt Perform by Leerink Swann
Leerink Swann rated Mkt Perform Elan Corporation, Plc (NYSE: ELN) on 02/25/2013. Previously Leerink Swann rated Underperform Elan Corporation, Plc (NYSE:
ELN) on 10/15/2012., when the stock price was $10.97. Since then, Elan Corporation, Plc has gained 2.28% as of 02/25/2013's recent price of $11.22. If you would have followed the previous Leerink Swann 's recommendation on ELN, you would have lost 2.22% of your investment in 133 days.
Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. Elan?s operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain. EDT focuses on the specialty pharmaceutical industry, including specialized drug delivery and manufacturing. In September 2009, the Company and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer`s Immunotherapy Program (AIP).
Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions.
Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann
to provide growth-focused clients an expertise earned through experience.